Frequency Therapeutics

Pioneering a new category in regenerative medicine, aiming to restore human function through progenitor cell activation. Lead program for remyelination in MS.

[Frequency Therapeutics @frequencytx]

March is #MSawarenessmonth, a time to recognize patients, the broader MS community, and the need to continuously advance scientific discovery in order to one day develop potentially restorative therapeutics.

[Frequency Therapeutics @frequencytx]

Frequency Chief Scientific Officer Dr. Christopher Loose, Ph.D., will present a company overview at the 33rd Annual Oppenheimer (Virtual) Healthcare Conference on March 13th at 8:00 am ET. A live webcast and a replay of the presentation can be accessed at https://t.co/rhv1vpKoOR.

[Frequency Therapeutics @frequencytx]

This International Women’s Day, Frequency honors the women who are advancing science and developing treatments to improve the health of others.

[Frequency Therapeutics @frequencytx]

Frequency Chief Scientific Officer Dr. Christopher Loose, Ph.D., will participate on a panel discussion at the 43rd Annual Cowen Healthcare Conference on March 8th at 12:50 p.m. ET. A live webcast and a replay of the presentation can be accessed at https://t.co/rhv1vpJQZj.

[Frequency Therapeutics @frequencytx]

Thrilled to announce the world-class neurologists and drug developers on our new Remyelination Clinical Advisory Board to help support our multiple sclerosis program – and that Nobel laureate, Dr. James Rothman, has joined our Regen Med Advisory Board. https://t.co/9MkCW4ZKkL

[Frequency Therapeutics @frequencytx]

Frequency is pleased to announce that the first patient has been dosed in the Phase 1b study of FX-345, our second hearing restoration candidate for individuals with sensorineural hearing loss. For more information: https://t.co/H0y7fpvwEU

[Frequency Therapeutics @frequencytx]

On Dec. 13, Frequency will host a virtual investor event with presentations from management and key opinion leaders, with a focus on its lead hearing restoration program, FX-322. To learn more: https://t.co/N4wjVf9ikD

[Frequency Therapeutics @frequencytx]

Frequency is proud to sponsor #VetsAid2022 and to support VetsAid's important work to raise funds for veterans organizations. #HearingLoss is one of the leading disabilities impacting veterans and we are thankful to @JoeWalsh for his commitment to this community.

[Frequency Therapeutics @frequencytx]

Today, Frequency shared its Q3 2022 financial results and recent business updates. Learn more: https://t.co/aPtYs6Lknu

[Frequency Therapeutics @frequencytx]

Frequency’s Co-founder and CSO Chris Loose spoke with @LongevityTech about our small molecule regenerative medicine approach that aims to activate the body’s ability to restore function and reverse degenerative diseases. Read more: https://t.co/uOFBybXXi4

[Longevity Technology @LongevityTech]

‘The next wave of regenerative medicine’
@frequencytx CSO on developing drugs that selectively activate the body’s innate regenerative capabilities.
#biotech #biotechnology #degenerativedisease #progenitorcells #regenerativemedicine
https://t.co/1UtV9gvVxD

[Frequency Therapeutics @frequencytx]

We were excited to join with colleagues in Amsterdam for #ECTRIMS2022 and to see the important research driving future MS treatments for patients.

[Frequency Therapeutics @frequencytx]

Today, Frequency Therapeutics announced enrollment completion of its Phase 2b study of FX-322, the Company’s lead hearing restoration candidate for individuals with sensorineural hearing loss. Study readout anticipated in Q1 2023. To learn more: https://t.co/bMfXvcrZNW

[Frequency Therapeutics @frequencytx]

The Frequency team enjoyed a great day at the annual Hearing Loss Association of America’s New England Walk4Hearing. Thrilled to be able to support HLAA and all of their essential programs! #HLAA #Walk4Hearing

[Frequency Therapeutics @frequencytx]

Frequency Co-Founder @MrJeffKarp spoke with Brigham Clinical & Research News about how insights from his research on stem cell regeneration in the gut led to our approach of activating cells in the inner ear that may help restore hearing. Read more: https://t.co/9EF7lAxkOy

[Frequency Therapeutics @frequencytx]

Frequency CEO David Lucchino will present a company overview at the Baird Healthcare Conference today at 12:50 pm EDT. A live webcast and a replay of the presentation can be accessed at https://t.co/bu2nEzAFFi

[Frequency Therapeutics @frequencytx]

Frequency CEO David L. Lucchino will present a company overview at H.C. Wainwright Global Healthcare Conference today at 11am EDT. A live webcast and replay of the presentation can be found at https://t.co/F2h09IbcJ7

[Frequency Therapeutics @frequencytx]

Today, Frequency announced its participation in investor and medical conferences coming up in September. Read more: https://t.co/6JuDugLJpN

[Frequency Therapeutics @frequencytx]

Today, Frequency shared its Q2 2022 financial results and recent business updates. https://t.co/60k1qMUj27

[Frequency Therapeutics @frequencytx]

Frequency is leading a new category of regenerative medicine – one that uses small molecules to "activate" a person's innate regenerative potential. Learn more about our science: https://t.co/nBCfhAh74P

[Frequency Therapeutics @frequencytx]

Frequency CSO Chris Loose will present a company overview at the upcoming H.C. Wainwright Global Investment Conference. The recorded presentation will be available 5/24 at 7am ET. https://t.co/KjG7PuGhnz